Hypothesis
Aged hematopoietic stem cells (HSCs) release mitochondria‑derived oxidative extracellular vesicles that transfer oxidized mtDNA to peripheral tissues, where it activates the cGAS‑STING pathway and drives a secondary wave of senescence independent of immune cell senescence. This positions mitochondrial ROS in HSCs as an upstream initiator of inflammaging, suggesting that rescuing HSC mitochondrial fidelity will attenuate both myeloid skewing and distal tissue aging more effectively than targeting senescent immune cells alone.
Mechanistic Rationale
Age‑associated DNA damage and mTOR hyperactivation in HSCs increase mitochondrial ROS production [1, 2]. Elevated ROS oxidizes mitochondrial DNA and promotes its packaging into exosomes that are released into circulation. Oxidized mtDNA is a potent agonist of cytosolic cGAS, triggering STING‑dependent IFN‑β production and NF‑κB activation in stromal cells [3]. The resulting paracrine SASP amplifies senescence in fibroblasts, endothelial cells and parenchyma, creating a feed‑forward loop that reinforces HSC myeloid bias via inflammatory cytokines feeding back on the marrow niche [4]. Thus, immune aging is not merely a consequence of senescence but is sparked by a mitochondrial signal that precedes lymphoid decline.
Testable Predictions
- In aged mice, intravenous injection of mitochondria‑targeted antioxidant MitoQ will reduce cir





























